Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Products under Development by Stage of Development | 8 | 1 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Products under Development by Therapy Area | 9 | 1 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Products under Development by Indication | 10 | 1 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Products under Development by Companies | 13 | 2 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Companies Involved in Therapeutics Development | 21 | 6 |
| Alteogen Inc. | 21 | 1 |
| Clearside BioMedical, Inc. | 22 | 1 |
| CSL Limited | 23 | 1 |
| Eli Lilly and Company | 24 | 1 |
| Formycon AG | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 26 | 1 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Drug Profiles | 27 | 24 |
| (aflibercept + nesvacumab) Drug Profile | 27 | 1 |
| (aflibercept + rinucumab) Drug Profile | 28 | 1 |
| (aflibercept + triamcinolone acetonide) Drug Profile | 29 | 3 |
| 2H-10 Drug Profile | 32 | 1 |
| aflibercept Drug Profile | 33 | 10 |
| aflibercept biosimilar Drug Profile | 43 | 1 |
| aflibercept biosimilar Drug Profile | 44 | 1 |
| CSL-346 Drug Profile | 45 | 1 |
| Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology Drug Profile | 46 | 1 |
| ziv-aflibercept Drug Profile | 47 | 4 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Dormant Projects | 51 | 1 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Discontinued Products | 52 | 1 |
| Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Featured News &Press Releases | 53 | 11 |
| Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists guidance | 53 | 1 |
| May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection | 54 | 1 |
| Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion | 54 | 1 |
| Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven | 55 | 1 |
| Feb 29, 2016: Formycon discloses details on second pipeline product FYB203 is a biosimilar for Eylea (aflibercept) | 56 | 1 |
| Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration | 56 | 1 |
| Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization | 57 | 1 |
| Sep 25, 2015: Bayer s Eye Drug Recommended for EU Approval in Fifth Indication | 57 | 1 |
| Sep 18, 2015: Three-Year Results with EYLEA Show Sustained Improvement in Vision for People with Diabetic Macular Edema | 58 | 1 |
| Jul 21, 2015: NICE gives green light to aflibercept solution for treating serious eye condition | 59 | 1 |
| Jun 26, 2015: Bayer Receives Approval for EYLEA for the Treatment of Retinal Vein Occlusion in Japan | 59 | 1 |
| Jun 02, 2015: NICE Recommended Aflibercept Solution For Injection For Treating Serious Diabetic Eye Condition In Final Draft Guidance | 60 | 1 |
| May 06, 2015: Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA in UK clinical practice | 60 | 2 |
| Apr 01, 2015: New Phase 3 Study in China Confirms Vision Improvement for Patients with Wet Age-Related Macular Degeneration when Receiving Aflibercept Solution for Intravitreal Injection | 62 | 1 |
| Mar 25, 2015: EYLEA (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema | 63 | 1 |
| Appendix | 64 | 2 |
| Methodology | 64 | 1 |
| Coverage | 64 | 1 |
| Secondary Research | 64 | 1 |
| Primary Research | 64 | 1 |
| Expert Panel Validation | 64 | 1 |
| Contact Us | 64 | 1 |
| Disclaimer | 65 | 1 |